, 12:335 | Cite as

Utility of single luteinizing hormone determination 3 h after depot leuprolide in monitoring therapy of gonadotropin-dependent precocious puberty

  • Shrikrishna V. Acharya
  • Raju A. Gopal
  • Joe George
  • Tushar R. Bandgar
  • Padma S. Menon
  • Nalini S. Shah


To determine utility of luteinizing hormone (LH) estimation, post intramuscular (IM) depot leuprolide in comparison with subcutaneous leuprolide stimulation test. Test for monitoring therapy in patients with gonadotropin dependent precocious puberty (GDPP). In seven patients of GDPP, who were treated with 11.25 mg depot leuprolide, the LH peak after subcutaneous (sc) test was compared with LH at hourly interval for 4 h after IM depot leuprolide for 13 tests and 3rd hour value for next ten tests. These two values were compared both before and after therapy. Before therapy, the mean ± SD LH peak after subcutaneous leuprolide stimulation test was 20.6 ± 7.85 IU/l (range 9.64–30.4 IU/l), and it was 27.3 ± 12.21 IU/l 3 h after the first depot leuprolide injection (range 10.5–45.4 IU/l). During therapy, the mean ± SD of LH peak after sc stimulation test was 1.96 ± 0.75 IU/l (range 1.1–3.1 IU/l), and it was 2.58 ± 0.54 IU/l (range 1.4–3.4 IU/l) 3 h after depot leuprolide injection. Three-hour LH value following IM depot leuprolide injection (11.25 mg) can be used for monitoring therapy in patients with GDPP because of its convenience and cost effectiveness.


Precocious puberty Gonadotropin Leuprolide Luteinizing hormone 


  1. 1.
    Toguchi H (1990) Pharmaceutical manipulation of leuprorelin acetate to improve clinical performance. J Int Med Res 18(Suppl 1):35–41PubMedGoogle Scholar
  2. 2.
    Parker KL, Baens-Bailon RG, Lee PA (1991) Depot leuprolide acetate dosage for sexual precocity. J Clin Endocrinol Metab 73:50–52CrossRefPubMedGoogle Scholar
  3. 3.
    Manasco PK, Pescovitz OH, Hill SC, Jones JM, Barnes KM, Hench KD, Loriaux DL, Cutler GB Jr (1989) Six year results of luteinizing hormone releasing (LHRH) agonist treatment in children with LHRH-dependent precocious puberty. J Pediatr 114:321–324CrossRefGoogle Scholar
  4. 4.
    Witchel SF, Baens-Bailon RG, Lee PA (1996) Treatment of central precocious puberty: comparison of urinary gonadotropin excretion and gonadotropin releasing hormone (GnRH) stimulation tests in monitoring GnRH analog therapy. J Clin Endocrinol Metab 81:1353–1356. doi: 10.1210/jc.81.4.1353 CrossRefPubMedGoogle Scholar
  5. 5.
    Cavallo A, Richards E, Busey S, Michaels SE (1995) A simplified gonadotrophin-releasing hormone test for precocious puberty. Clin Endocrinol (Oxf) 42:641–646. doi: 10.1111/j.1365-2265.1995.tb02692.x CrossRefGoogle Scholar
  6. 6.
    Bhatia S, Neely EK, Wilson DM (2002) Serum luteinizing hormone rises within minutes after depot leuprolide injection: implications for monitoring therapy. Pediatrics 109:E30. doi: 10.1542/peds.109.2.e30 CrossRefPubMedGoogle Scholar
  7. 7.
    Lahlou N, Carel JC, Chaussain JL, Roger M (2000) Pharmacokinetics and pharmacodynamics of GnRH agonists: clinical implications in pediatrics. J Pediatr Endocrinol Metab 13:723–737PubMedGoogle Scholar
  8. 8.
    Greulich WW, Pyle SI (1959) Radiographic atlas of skeletal development of the hand and wrist. Stanford University Press, StanfordGoogle Scholar
  9. 9.
    Brito VN, Batista MC, Borges MF, Latronico AC, Kohek MBF, Thirone ACP, Jorge BH, Arnhold IJP, Mendonca BB (1999) Diagnostic value of fluorometric assays in the evaluation of precocious puberty. J Clin Endocrinol Metab 84:3539–3544. doi: 10.1210/jc.84.10.3539 CrossRefPubMedGoogle Scholar
  10. 10.
    Lee PA (1994) Laboratory monitoring of children with precocious puberty. Arch Pediatr Adolesc Med 148:369–376PubMedGoogle Scholar
  11. 11.
    Lawson ML, Cohen N (1999) A single sample subcutaneous luteinizing hormone (LH)-releasing hormone (LHRH) stimulation test for monitoring LH suppression in children with central precocious puberty receiving LHRH agonists. J Clin Endocrinol Metab 84:4536–4540. doi: 10.1210/jc.84.12.4536 CrossRefPubMedGoogle Scholar
  12. 12.
    Cook JS, Doty KL, Conn PM, Hansen JR (1992) Assesment of depot Lupron dose-adequacy for central precocious puberty. J Clin Endocrinol Metab 74:1206–1209. doi: 10.1210/jc.74.5.1206 CrossRefPubMedGoogle Scholar
  13. 13.
    Salerno M, Di Maio S, Gasparini N, Mariano A, Macchia V, Tenore A (1998) Central precocious puberty: a single blood sample after gonadotropin-releasing hormone agonist administration in monitoring treatment. Horm Res 50(4):205–211. doi: 10.1159/000023275 CrossRefPubMedGoogle Scholar
  14. 14.
    Brito VN, Latronico AC, Arnhold IJP, Mendonca BB (2004) A single luteinizing hormone determination 2 hours after depot leuprolide is useful for therapy monitoring of gonadotropin-dependent precocious puberty in girls. J Clin Endocrinol Metab 89(9):4338–4342. doi: 10.1210/jc.2003-031537 CrossRefPubMedGoogle Scholar
  15. 15.
    Antoniazzi F, Cisternino M, Nizzoli G, Bozzola M, Corrias A, De Luca F, De Sanctis C, Rigon F, Zamboni G, Bernasconi S (1994) Final height in girls with central precocious puberty: comparison of two different luteinizing hormone-releasing hormone agonist treatments. Acta Paediatr 83:1052–1056. doi: 10.1111/j.1651-2227.1994.tb12984.x CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • Shrikrishna V. Acharya
    • 1
  • Raju A. Gopal
    • 1
  • Joe George
    • 1
  • Tushar R. Bandgar
    • 1
  • Padma S. Menon
    • 1
  • Nalini S. Shah
    • 1
  1. 1.Department of EndocrinologyK E M HospitalMumbai-12India

Personalised recommendations